110 related articles for article (PubMed ID: 15304171)
1. The European Canadian Intergroup trial (OV10 trial) and the US Gynaecologic Oncology Group trial (GOG 111).
Swart AM; Parmar MK; Harper P; Colombo N; Torri V
Int J Gynecol Cancer; 2004; 14(4):697; author reply 698. PubMed ID: 15304171
[No Abstract] [Full Text] [Related]
2. ICON2 trial. EORTC-GCCG, NOCOVA, NCI-C, Scottish groups, and GOG. Gynaecologic Oncology Group.
Piccart MJ; McGuire WP
Lancet; 1999 Feb; 353(9152):587; author reply 588. PubMed ID: 10029002
[No Abstract] [Full Text] [Related]
3. First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence.
Sandercock J; Parmar MK; Torri V
Br J Cancer; 1998 Dec; 78(11):1471-8. PubMed ID: 9836480
[TBL] [Abstract][Full Text] [Related]
4. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin versus cisplatin in ovarian cancer.
Alberts DS
Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
[TBL] [Abstract][Full Text] [Related]
6. Gynecologic oncology group trials in ovarian carcinoma.
Ozols RF
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-10-S2-12. PubMed ID: 9045325
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy of advanced ovarian cancer: current status and future directions.
Ozols RF; Vermorken JB
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-1-S2-9. PubMed ID: 9045324
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when?
Echarri Gonzalez MJ; Green R; Muggia FM
Oncology (Williston Park); 2011 Feb; 25(2):156-65, 170. PubMed ID: 21456387
[TBL] [Abstract][Full Text] [Related]
9. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study.
Almadrones L; McGuire DB; Walczak JR; Florio CM; Tian C
Oncol Nurs Forum; 2004 May; 31(3):615-23. PubMed ID: 15146227
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal therapy for advanced ovarian cancer: will it become standard care?
Bankhead C
J Natl Cancer Inst; 2006 Apr; 98(8):510-2. PubMed ID: 16622116
[No Abstract] [Full Text] [Related]
11. Chemotherapy for ovarian cancer.
Cvitkovic E; Misset JL
N Engl J Med; 1996 May; 334(19):1269; author reply 1270. PubMed ID: 8606730
[No Abstract] [Full Text] [Related]
12. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy for ovarian cancer--trials, controversies and funding.
Hawkins RE
Br J Cancer; 1998 Dec; 78(11):1402-3. PubMed ID: 9836469
[No Abstract] [Full Text] [Related]
14. Chemotherapy for ovarian cancer.
Parmar MK; Sandercock J
N Engl J Med; 1996 May; 334(19):1268-9; author reply 1270. PubMed ID: 8606729
[No Abstract] [Full Text] [Related]
15. Current status and future directions of platinum/paclitaxel-based chemotherapy of ovarian cancer.
Markman M
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-24-S11-27. PubMed ID: 9314295
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium.
Neymark N; Gorlia T; Adriaenssen I; Baron B; Piccart M
Pharmacoeconomics; 2002; 20(7):485-97. PubMed ID: 12093304
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
[TBL] [Abstract][Full Text] [Related]
18. ICON3 and chemotherapy for ovarian cancer.
Ozols RF; Markman M; Thigpen JT
Lancet; 2002 Dec 21-28; 360(9350):2086-7; author reply 2088. PubMed ID: 12504453
[No Abstract] [Full Text] [Related]
19. ICON2 trial. UK consensus statement on standard practice for chemotherapy in ovarian cancer.
Gore ME
Lancet; 1999 Feb; 353(9152):587-8. PubMed ID: 10029003
[No Abstract] [Full Text] [Related]
20. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study.
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-13-S2-16. PubMed ID: 9045329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
